The tour spotlighted US BioDesign's highly specialized capabilities, clean room technology and state-of-the-art manufacturing equipment, which includes the world's largest medical braider and custom-designed processes for nonwoven medical felts. According to Molz, the facility expansion supports the company's business strategy for remaining competitive, despite the Affordable Care Act's economic impact on the global medical device industry.
"The Affordable Care Act mandates a 2.3% tax on the sale of medical devices, which means our customers have to do more with less," says Keith Smith, director of business development. "Our streamlined approach to new product development enables the most cost effective use of resources, helping medical device companies address this challenge."
According to Molz, unlike some long established suppliers to the medical device industry, US BioDesign is a new company with an agile and flexible operating structure designed to support its singular founding mission: To serve the medical device industry as a highly capable, yet cost efficient supplier of engineered medical textiles, biomedical structures and implantable fabrics.
"Our business strategy," he says, "advances that mission and positions US BioDesign as the foremost industry resource for expert, highly reliable, highly capable, high quality yet cost efficient medical fabric development and manufacturing solutions."